Physician profile
Jack W Li
NPI 1245653054
$3,821.89
in general payments reported to CMS, 2019-2025
29 companies · $1,393 in 2025
The $1,393 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.05 · 2022: $370 · 2023: $652 · 2024: $1,392 · 2025: $1,393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,417 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,417.19 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $544.18 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $455.42 | 2022-2025 | Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $445.46 | 2022-2025 | |
| Abbott Laboratories | $380.52 | 2022-2025 | Freestyle Libre 3, Mitraclip, Thoratec Heartmate 3 Lvas Implant Kit |
| Merck Sharp & Dohme LLC | $335.26 | 2022-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Pfizer INC. | $244.89 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $197.19 | 2023-2025 | Farxiga, Wainua, Lokelma |
| Amgen INC. | $192.87 | 2022-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $121.34 | 2024-2025 | Camzyos, Eliquis |
| Scpharmaceuticals INC. | $114.47 | 2024-2025 | |
| Exact Sciences Corporation | $107.48 | 2023-2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.35 | 2024-2025 | Jardiance |
| Shield Therapeutics INC | $73.66 | 2025 | |
| Esperion Therapeutics, INC. | $72.06 | 2023-2024 | Nexletol |
| Regeneron Healthcare Solutions, INC. | $66.45 | 2024-2025 | Evkeeza |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $53.98 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $47.37 | 2024 | Arcalyst |
| Inspire Medical Systems, INC. | $41.96 | 2025 | Inspire |
| Abbvie INC. | $35.61 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $26.73 | 2023 | |
| Tactile Systems Technology INC | $26.31 | 2025 | Flexitouch Plus, Nimbl |
| Philips North America LLC | $26.08 | 2025 | Mcot |
| Kiniksa Pharmaceuticals, Ltd. | $25.07 | 2023 | Arcalyst |
| Althera Pharmaceuticals LLC | $24.33 | 2022 | |
| Medicure Pharma INC. | $20.50 | 2024 | Zypitamag |
| Dexcom, INC. | $18.38 | 2023 | Dexcom G6 Transmitter |
| Gilead Sciences, INC. | $16.55 | 2023 | |
| Glaxosmithkline, LLC. | $14.37 | 2025 | Trelegy Ellipta |
| Biogen, INC. | $14.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.